Limits...
Enhanced production of IGF-I in the lungs of fibroproliferative ARDS patients.

Andonegui G, Krein PM, Mowat C, Brisebois R, Doig C, Green FH, Léger C, Winston BW - Physiol Rep (2014)

Bottom Line: Our data show that IGF-I is significantly increased in the ELF in FP-ARDS patients.A significant correlation between IGF-I and PCP-III in the ELF of FP-ARDS patients is found.Our data suggest that IGF-I found in the lungs of FP-ARDS patients results from both increased lung permeability and local production of IGF-I.

View Article: PubMed Central - PubMed

Affiliation: Department of Critical Care Medicine, Faculty of Medicine, University of Calgary Health Research Innovation Center, Calgary, Alberta, Canada Immunology Research Group, Faculty of Medicine, University of Calgary Health Research Innovation Center, Calgary, Alberta, Canada.

No MeSH data available.


Related in: MedlinePlus

Real‐Time qRT‐PCR of Lung Biopsy Specimens. mRNA levels measured in control (n = 4 in triplicate) and FP‐ARDS (n = 2 in triplicate) lung biopsy specimens. Threshold values (CT) were subtracted from rRNA threshold value giving dCT for each patient. Displayed are average dCT values. A more negative number indicates higher mRNA expression. (A) CD68 mRNA quantified from lung biopsy specimens in control and FP‐ARDS biopsies. (B) IGF‐I mRNA quantified from control and FP‐ARDS lung biopsy specimens. IGF‐I mRNA is below the level of detection in control lung biopsy specimens. Of note, there are increased IGF‐I mRNA levels in the FP‐ARDS patients compared to controls. This difference is not seen when CD68 mRNA (a macrophage marker) is measured in control and FP‐ARDS lung biopsy specimens.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4255805&req=5

fig05: Real‐Time qRT‐PCR of Lung Biopsy Specimens. mRNA levels measured in control (n = 4 in triplicate) and FP‐ARDS (n = 2 in triplicate) lung biopsy specimens. Threshold values (CT) were subtracted from rRNA threshold value giving dCT for each patient. Displayed are average dCT values. A more negative number indicates higher mRNA expression. (A) CD68 mRNA quantified from lung biopsy specimens in control and FP‐ARDS biopsies. (B) IGF‐I mRNA quantified from control and FP‐ARDS lung biopsy specimens. IGF‐I mRNA is below the level of detection in control lung biopsy specimens. Of note, there are increased IGF‐I mRNA levels in the FP‐ARDS patients compared to controls. This difference is not seen when CD68 mRNA (a macrophage marker) is measured in control and FP‐ARDS lung biopsy specimens.

Mentions: All tests were performed using the STATVIEW software (SAS, Cary, NC). A 95% confidence interval (CI) was used in all the statistical analysis. Statistical differences between BALF and serum proteins and mRNA levels were calculated using the Mann–Whitney U‐test. Immunohistochemical correlations were assessed with Spearman's Rank Sum test. Data are represented as mean ± SEM. A P < 0.05 was considered significant. For IGF‐I mRNA levels in the lungs, since only 2 FP‐ARDS lung biopsies and four control biopsies were done, the data are presented as mean values without statistical analysis, that is, no error bars are shown in Fig. 5.


Enhanced production of IGF-I in the lungs of fibroproliferative ARDS patients.

Andonegui G, Krein PM, Mowat C, Brisebois R, Doig C, Green FH, Léger C, Winston BW - Physiol Rep (2014)

Real‐Time qRT‐PCR of Lung Biopsy Specimens. mRNA levels measured in control (n = 4 in triplicate) and FP‐ARDS (n = 2 in triplicate) lung biopsy specimens. Threshold values (CT) were subtracted from rRNA threshold value giving dCT for each patient. Displayed are average dCT values. A more negative number indicates higher mRNA expression. (A) CD68 mRNA quantified from lung biopsy specimens in control and FP‐ARDS biopsies. (B) IGF‐I mRNA quantified from control and FP‐ARDS lung biopsy specimens. IGF‐I mRNA is below the level of detection in control lung biopsy specimens. Of note, there are increased IGF‐I mRNA levels in the FP‐ARDS patients compared to controls. This difference is not seen when CD68 mRNA (a macrophage marker) is measured in control and FP‐ARDS lung biopsy specimens.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4255805&req=5

fig05: Real‐Time qRT‐PCR of Lung Biopsy Specimens. mRNA levels measured in control (n = 4 in triplicate) and FP‐ARDS (n = 2 in triplicate) lung biopsy specimens. Threshold values (CT) were subtracted from rRNA threshold value giving dCT for each patient. Displayed are average dCT values. A more negative number indicates higher mRNA expression. (A) CD68 mRNA quantified from lung biopsy specimens in control and FP‐ARDS biopsies. (B) IGF‐I mRNA quantified from control and FP‐ARDS lung biopsy specimens. IGF‐I mRNA is below the level of detection in control lung biopsy specimens. Of note, there are increased IGF‐I mRNA levels in the FP‐ARDS patients compared to controls. This difference is not seen when CD68 mRNA (a macrophage marker) is measured in control and FP‐ARDS lung biopsy specimens.
Mentions: All tests were performed using the STATVIEW software (SAS, Cary, NC). A 95% confidence interval (CI) was used in all the statistical analysis. Statistical differences between BALF and serum proteins and mRNA levels were calculated using the Mann–Whitney U‐test. Immunohistochemical correlations were assessed with Spearman's Rank Sum test. Data are represented as mean ± SEM. A P < 0.05 was considered significant. For IGF‐I mRNA levels in the lungs, since only 2 FP‐ARDS lung biopsies and four control biopsies were done, the data are presented as mean values without statistical analysis, that is, no error bars are shown in Fig. 5.

Bottom Line: Our data show that IGF-I is significantly increased in the ELF in FP-ARDS patients.A significant correlation between IGF-I and PCP-III in the ELF of FP-ARDS patients is found.Our data suggest that IGF-I found in the lungs of FP-ARDS patients results from both increased lung permeability and local production of IGF-I.

View Article: PubMed Central - PubMed

Affiliation: Department of Critical Care Medicine, Faculty of Medicine, University of Calgary Health Research Innovation Center, Calgary, Alberta, Canada Immunology Research Group, Faculty of Medicine, University of Calgary Health Research Innovation Center, Calgary, Alberta, Canada.

No MeSH data available.


Related in: MedlinePlus